Trailing-twelve-month (TTM) revenue is $355.17 Million with a year-over-year growth of (2.36%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $113,725,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-29 |
| Q4 FY2025Period ended 2025-12-31 | $118,095,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-25 |
| Q1 FY2026Period ended 2026-03-31 | $58,991,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-29 |
| Q2 FY2026Period ended 2026-06-30 | $64,362,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-29 |
| TTM revenue | $355,173,000 |
Current P/S: $670,410,697 market capitalization ÷ $355,173,000 TTM revenue = 1.89x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T16:45:30.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $64.36M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:48:12.010Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20162016-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|
| Advanced Wound Care, Tissue And Other | N/A | $216M | $242M | N/A | N/A |
| Advanced Wound Care, Umbilical Cord-Derived | N/A | $24M | $23M | N/A |
$355.17M
$355.17 Million
(2.36%)
vs. $363.76M a year ago (TTM)
+6.36%
5 Year compound annual growth rate
1 Year
(2.36%)
3 Year
+6.38%
5 Year
+6.36%
10 Year
+5.32%
15 Year
+36.53%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $418.63M | +$69.75M | +19.99% |
| 2024 | $348.88M | +$27.40M | +8.52% |
| 2023 | $321.48M | +$53.64M | +20.03% |
| 2022 | $267.84M | +$25.82M | +10.67% |
| 2021 | $242.02M | ($6.21M) | (2.50%) |
| 2020 |
TTM Growth
(2.36%)
3-Year CAGR
+6.38%
5-Year CAGR
+6.36%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T16:48:12.010Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| N/A |
| Health Care | N/A | $240M | $265M | N/A | N/A |
|---|
| Product and Service, Other | N/A | $988,000 | $259,000 | N/A | N/A |
|---|
| Section 351 | N/A | $18M | $2M | N/A | N/A |
|---|
| Surgical | N/A | N/A | N/A | $118M | $142M |
|---|
| Surgical, Sports Medicine & Orthopedics (SSO) | $61M | N/A | N/A | N/A | N/A |
|---|
| Wound Care | $184M | N/A | N/A | N/A | N/A |
|---|
| $248.23M |
| ($51.02M) |
| (17.05%) |
| 2019 | $299.25M | ($59.86M) | (16.67%) |
| 2018 | $359.11M | +$37.97M | +11.82% |
| 2017 | $321.14M | +$76.12M | +31.07% |
| 2016 | $245.01M | +$57.72M | +30.82% |
